OpenEvidence, a three-year-old AI business known as “ChatGPT for doctors,” has raised a fresh $250 million fundraising round this weekend, doubling its worth to over $12 billion.
The AI tool for healthcare helps physicians swiftly obtain evidence-based responses by analyzing medical research and journal articles.
The rise in valuation, published on December 14, 2025, illustrates a growing investor interest for specialized AI tools with clear real-world value, beyond general-purpose chatbots. OpenEvidence’s revenue growth and adoption by medical experts bolstered venture backers’ trust.
What this means for creators
You don’t have to be in healthcare to understand the message here. AI tools that handle specific, real-world problems are extremely valuable.
Investors and customers are interested in content, apps, lessons, or services that cater to certain niches, such as education, legal assistance, or creative tech workflows.
Also Read: Anything named No. 1 vibe coding tool: a new boost for indie app creators
What this means for entrepreneurs
This is more than simply hype; it is capital seeking genuine utility.
A $12 billion valuation demonstrates that AI apps with proven value and paying users can attract significant funding.
In today’s competitive AI startup scene, founders must prioritise clear product-market fit and measurable impact.
